^
Association details:
| Biomarker: | NF1 rearrangement |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification.
Published date:
05/19/2021
Excerpt:
Table summarizes matched therapies in responders....Undifferentiated pleomorphic sarcoma...NF1: rearrangement...Trametinib – SD, 2 mo.
DOI:
10.1200/JCO.2021.39.15_suppl.11538
